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ABSTRACT OF THE DISSERTATION
CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE): EPIDEMIOLOGY,
DURATION OF CARRIAGE, AND PROGRESSION TO INFECTION IN A LARGE
HEALTHCARE SYSTEM IN MIAMI, FL
by
Adriana Jimenez
Florida International University, 2020
Miami, Florida
Professor Mary Jo Trepka, Major Professor
Carbapenem-resistant Enterobacteriaceae (CRE) are multidrug-resistant
organisms (MDRO) considered by the CDC as an urgent public health threat that is
spreading globally. Little is known about the epidemiology of CRE in Miami, FL. The
purpose of this dissertation was to 1) Evaluate trends in the epidemiology of CRE among
patients admitted to the acute care facilities of the largest healthcare system in Miami, FL
between 2012 and 2016, 2) Identify factors associated with progressing to infection
among patients colonized with carbapenemase-producing Enterobacteriaceae (CPE), and
3) Determine the duration of CPE carriage and factors associated with long-term carriage
in our cohort.
A total of 371 CRE cases were identified retrospectively. The overall prevalence
was 0.077 per 100 patient-admissions; the admission prevalence was 0.019 per 100
patient-admissions, and the incidence density was 1.46 cases per 10,000 patient-days.
Rates increased during the first three years of the study and declined in the last two.
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Of 54 patients colonized with CPE, 16 (30%) of them developed CPE infections.
The mean time for infection development was 63 days. Cox regression analysis identified
the use of an indwelling urinary catheter (HR 4.4; P-value=0.034), exposure to
intravenous colistin (HR 3.2; P-value=0.037), and transfer from overseas facilities (HR
9.8; P-value=0.021) as variables associated with the development of infection.
Additionally, out of 75 eligible patients, 25 (33%) were cleared from CPE-carrier status.
Immunocompromised patients, those that had mechanical ventilation exposure, or
exposure to carbapenems had a lower probability of being cleared from CPE-carrier
status (HR 0.34; 0.34, and 0.14 respectively (P-value <0.05]). Having CPE isolated from
>1 anatomical body site was associated with a 5.3 times higher probability of being
cleared from CPE-carrier status (P-value <0.001). The median time for clearance was 80
days (Range 16-457).
In conclusion, the use of MDRO registries and active surveillance testing
contribute to control increasing rates of CRE. Furthermore, infection prevention and
antimicrobial stewardship interventions aimed to decrease unnecessary use of medical
devices and rapid selection of effective treatment are key factors to prevent the
development of CPE-related infections among CPE colonized patients as well as to
prevent long-term CPE carriage.
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INTRODUCTION
Carbapenem-resistant Enterobacteriaceae (CRE) are Gram-negative bacilli that are
resistant to carbapenems. Carbapenems are broad-spectrum antibiotics considered as the
last resort for the treatment of Enterobacteriaceae infections.1 The Centers for Disease
Control and Prevention (CDC) and the World Health Organization (WHO) classified
CRE as an urgent threat that requires public health attention for treatment and prevention
and a critical priority for research.2,3 In 2019, the CDC estimated about 13,100 infections
by CRE and about 1,100 deaths in the United States.3 The most common species of CRE
in the US are Klebsiella pneumoniae, Enterobacter aerogenes/cloacae, and Escherichia
coli with reports of 5.7 %, 4.8 %, and 0.6 % of them being carbapenem-resistant
respectively.3,4 Most of the CRE cases in the US are reported from the East-NorthCentral, Mid-Atlantic, and South-Atlantic areas.4 CRE infections are associated with
increased morbidity, mortality, and extended hospital length of stay (LOS).1,3,5-7
CRE are not among the reportable diseases/conditions in Florida.8 Therefore, there are
limited data about the incidence of CRE in Miami-Dade County. CRE have been
described in Florida since 2008 but mainly during various outbreaks.9-11 Miami-Dade
County is constantly receiving visitors and immigrants from different parts of the world
known to be endemic with CRE; 6,12 this poses a high risk for the spread of CRE in the
South Florida community. According to the CDC’s Antibiotic Resistance & Patient
Safety Portal, the CRE estimate for select healthcare-associated infections (HAIs) is 2.7%
for the US and 2.1% for Florida for the period of 2011 to 2018.4 This percentage is based
on only three HAI types reported to the CDC (Central line associated bloodstream
infection [CLABSI], catheter associated urinary tract infection [CAUTI], surgical site
1

infection [SSI]). The report excludes isolates from other HAIs, as well as communityacquired conditions, and isolates from active surveillance testing; therefore it does not
reflect the total burden of CRE in the US.4
Carbapenem-resistant Enterobacteriaceae (CRE) can be resistant to carbapenems by
different mechanisms including augmented drug efflux, a mutation in or loss of outer
membrane porins, and production of carbapenemases.6,13,14 Carbapenemases are a type of
β-lactamases that breakdown carbapenems, making the treatment with this class of
antibiotics ineffective. Although CRE poses a challenge for the patient’s antibiotic
therapy, carbapenemase-producing Enterobacteriaceae (CPE) present a bigger problem
for infection prevention, and treatment, since carbapenemase production is frequently
plasmid-mediated; plasmids give the microorganism the capability to transfer genetic
information for carbapenems resistance to other species of Gram-negative bacilli (i.e.
other Enterobacteriaceae, Pseudomonas or Acinetobacter).14 In 2017 Tamma et al.,
reported that the odds of dying among patients that developed bloodstream infection
(BSI) by CPE are five times higher compared to those with BSI caused by non-CPE.15
Since the first reports in the early 1990s, CPE has spread across the world.6,7,14
There are four classes of β-lactamases associated with carbapenem resistance: A, B, C,
and D. Classes A, C, and D are serine enzymes, and class B includes metalloenzymes.
This differentiation is important because metallo-β-lactamases are not inhibited by
avibactam; combinations of avibactam are currently used to treat CPE infections.16 In
class A, Klebsiella pneumoniae carbapenemase (KPC) is the most important; KPC
enzyme production is plasmid-mediated and considered endemic in the United States,
Argentina, Brazil, Colombia, Italy, Greece, Israel, and China.6,7,14,17-19 Class A also
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includes the less common Guiana extended-spectrum β-lactamase (GES), and Serratia
marcescens enzyme (SME). Class B carbapenemases are metallo-β-lactamases (MBLs)
and include imipenemase (IMP), Verona integrin-encoded MBL (VIM), and New Delhi
MBL (NDM); class B carbapenemases are more common in certain areas of Asia and
Europe; nevertheless, there have been case reports and sporadic outbreaks across several
states in the US caused by organisms carrying these carbapenemases.6,16 Class C includes
ampC, CMY, and ACT; these carbapenemases are less common. Finally, class D
carbapenemases are plasmid-mediated oxacillin-hydrolyzing β-lactamases; OXA 23,
OXA-48, and OXA-58 are the most frequently found. OXA-48 is considered endemic in
some Mediterranean countries such as Turkey, France, and Spain; there have been case
reports and sporadic outbreaks reported throughout the United States.6,16,20
Previous studies have assessed risk factors associated with infection and carriage with
CPE among pediatric and adult populations identifying risk factors for special
populations such as neonates, solid organ transplant recipients, and oncology patients,
among others. These risk factors include admission to intensive care units (ICU), use of
invasive devices such as ventilators, comorbidities, invasive procedures, exposure to
hospital care, CPE exposure, solid organ transplant, living in long term care facilities, and
antibiotic exposure.21-23 One important risk factor identified in several studies for CPE
infection is previous colonization with these organisms; CPE colonization increases the
odds up to ten times for developing systemic infections caused by CPE.24 Moreover not
all patients who acquire CPE develop infections by these organisms, with many
remaining only colonized.24-27 A recent systematic review found that, overall, 16% of
patients colonized with CRE develop infections.28 Most studies in the US are related to
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the acquisition of CRE/CPE or the development of infection among at-risk
populations.5,17,23,29-32 There are few studies assessing variables associated with
progression to infection among adults colonized in the acute care setting.28 One study
among a pediatric population found that underlying metabolic disease, previous
carbapenem exposure, neutropenia, and previous surgical procedure are independent risk
factors for carbapenem-resistant Klebsiella pneumoniae (CR-KP) infection in patients
previously colonized with the same organism.33 Most studies related to colonization with
CPE are from Israel or Europe, and their results cannot necessarily be extrapolated to the
US due to differences in antibiotic use, practices, and prevalent carbapenemase.28
Furthermore, most of these studies address questions related only to Klebsiella
pneumoniae leaving a gap in knowledge for other species of Enterobacteriaceae. There
are limited data available that allow identification of factors associated with the
development of clinical infection by CPE in patients colonized by the same organism in
the US. The few reports are limited to rectal colonization, leaving a knowledge gap about
factors associated with infection due to colonization in other body sites.25,26
In 2015 the CDC issued a toolkit with recommendations for healthcare facilities to
prevent and control the spread of CRE.1 These recommendations include monitoring and
promoting hand hygiene compliance, placing CRE patients on contact precautions (CP),
staff education, minimizing the use of devices, timely notification by the laboratory,
inter-facility communication for patient transfers, establishing antimicrobial stewardship
programs, daily environmental cleaning of areas nearby of the patient, patient and staff
cohorting using dedicated staff for CRE patients, screening contact of CRE patients,
active surveillance testing particularly high-risk populations, and chlorhexidine (CHG)
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bathing.1 Unfortunately, CDC recommendations do not provide guidance on how long a
patient, either colonized or infected with CRE/ CPE, should be placed in CP to prevent
horizontal transmission in acute care facilities; there is not enough evidence yet to make
such recommendations,1 leaving it up to the facility to determine how long to maintain
CP for these patients during index admission and readmissions. Placing patients on CP
indefinitely with dedicated staff places an extra burden on the facility. Few studies have
assessed the duration of carriage of CPE, most of them in Israel.27,34-38 There is limited
research about this topic in the US. Recently, the Society for Healthcare Epidemiology of
America (SHEA) published an expert guidance for duration of CP for acute-care facilities
that includes CP for CRE among other multidrug resistant organisms; this expert
guidance was based on a systematic review and a survey distributed among the SHEA
research network.39 In the systematic review, the authors found wide variability on
median time for carriage clearance. Again, most studies included in the review were from
Israel, China, or Europe. In the SHEA survey, only 32% of the facilities reported having
policies that allow discontinuation of CP for CRE; 28% reported using screening tests for
discontinuing CP; 38% reported using a ‘greater than 1 year since last positive test’ rule
to discontinue CP. The expert guidance recommends maintaining CP indefinitely for
extensively drug-resistant Enterobacteriaceae such as CP-CRE.39 More recently, the
European Centre for Disease Prevention and Control published their expert guidance for
infection prevention control and management of CRE in healthcare facilities;40 this
guidance recommends to discontinue contact precautions on patients with history of CRE
carriage on a case-by-case assessment based on patient risk factors for prolonged
carriage.40

5

In conclusion, little is known about the epidemiology of CRE in Miami-Dade County, as
well as factors associated with the development of CPE-related infections among those
previously colonized, or when is appropriated to discontinue CP for patients with a
history of CPE-carriage.
The overall aim of this dissertation was to evaluate trends in the epidemiology of CRE
and CPE among patients admitted to acute care facilities of Miami-Dade County. We also
aimed to identify risk factors associated with the development of CPE-related infections
among previously colonized patients and to evaluate the median duration of CPE carriage
and identify factors related to a long-term carriage. We conducted three retrospective
cohort studies among patients admitted to any of the acute care facilities of the largest
healthcare system in Miami-Dade County between 2012-2016. This dissertation
contributes to the field by providing information for public health authorities and the
healthcare community in Miami-Dade County about possible unrecognized trends in
antimicrobial resistance in the community through incidence density rate of CRE and CPCRE; identification of populations at risk for CPE infection in the community, and a
baseline for guidance for infection control management of CPE carriage in acute care
settings not only in Miami-Dade County, but also across the US and other areas in the
world with similar CRE epidemiology.
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MANUSCRIPT 1
© Copyright 2020
Epidemiology of carbapenem-resistant Enterobacteriaceae in hospitals of a large
healthcare system in Miami, Florida from 2012 to 2016: Five years of experience
with an internal registry
Abstract
Background: Carbapenem-resistant Enterobacteriaceae (CRE) is an urgent public health
threat globally. Limited data are available regarding the epidemiology of CRE in South
Florida.
We describe the epidemiology of CRE within a large public healthcare system in Miami,
FL, the experience with an internal registry, active surveillance testing, and the impact of
infection prevention practices.
Methods: Retrospective cohort study in four hospitals from a large healthcare system in
Miami-Dade County, FL from 2012 to 2016. The internal registry included all CRE cases
from active surveillance testing from rectal/tracheal screening occurring in the ICUs of
two of the hospitals and clinical cultures across the healthcare system. All CRE cases
were tagged in the electronic medical record and automatically entered into a platform for
automatic infection control surveillance. The system alerted about new cases,
readmissions, and transfers.
Results: A total of 371 CRE cases were identified. The overall prevalence was 0.077
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cases per 100 patient-admissions; the admission prevalence was 0.019 per 100 patientadmissions, and the incidence density was 1.46 cases per 10,000 patient-days. Rates
increased during the first three years of the study and declined later to a lower level than
at the beginning of study period.
Conclusion: Active surveillance testing and the use of an internal registry facilitated
prompt identification of cases contributing to control of increasing rates of CRE by rapid
implementation of infection prevention strategies.
Background
Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent public health
threat because of their current rapid spread around the world, and high morbidity and
mortality.1,2 The Centers for Disease Control and Prevention (CDC) estimates that there
are approximately 13,100 new infections and approximately 1,100 deaths by CRE over
time from 2012 -2017.1 Recent publications estimate that the CRE incidence in the US
ranges between 0.46 and 4.17 cases per 10,000 patient-days,3 and it is more prevalent in
highly populated areas such as California, Chicago, and New York.4-6 Risk factors for
CRE acquisition have been extensively described and include the presence of medical
devices, prolonged stay in healthcare facilities, surgery, antibiotic exposure, solid organ
transplant, and travel to endemic areas.1,7 Among the different mechanisms for
carbapenem resistance, carbapenemase production is of major concern because it spreads
easily, as it is frequently plasmid-mediated; genetic information can be shared among
different bacterial species by this mechanism.7-9
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Despite recent efforts, little is known about the epidemiology of CRE in South
Florida, in part because these organisms are not reportable in the state.10 Therefore, there
are limited data about the burden of CRE in the region, although cases have been
sporadically described in the state since 2008.11-13 According to the CDC in Florida, 2.5%
of the Enterobacteriaceae related to healthcare-associated infections (HAI) are CRE.14
This percentage is based on central line-associated bloodstream infections, catheterassociated urinary tract infections, and surgical-site infections; it excludes isolates from
other HAI, as well as community-acquired infections, and isolates from active
surveillance testing.14 The Florida Department of Health (FL-DOH) has developed
collaborative efforts for CRE surveillance and prevention;15 one of them found
carbapenem-resistant Klebsiella pneumoniae (CR-KP) incidence density of 0.473 per
10,000 patient-days in 2014 (unpublished data). The study also indicated that MiamiDade County facilities had higher CR-KP incidence than facilities from other counties.
Additionally, since 2014, FL-DOH requires all laboratories participating in the electronic
laboratory reporting (ELR) to submit the susceptibility testing results of Klebsiella
species, Escherichia coli, Enterobacter species, Citrobacter species, and Serratia species
from sterile sites;16 moreover, participation in ELR is not mandatory. The use of
statewide CRE registries has been recently reported to contribute to the control of CRE
spreading by tracking patients who are carrying these organisms and notifying the
admitting healthcare facility so proper infection prevention precautions can be started
timely.17,18
Miami-Dade County is the seventh-largest county in the US and regularly
receives visitors and immigrants from different parts of the world known to have endemic
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CRE such as Venezuela, Brazil, and Colombia.7,19 Thus, South Florida is one of the main
entry points in the US for CRE from South America making the understanding of its
epidemiology of great importance. Currently neither the state of Florida nor Miami-Dade
County count with a state wide CRE registry. Here we aimed to describe the
epidemiology of CRE comparing carbapenemase-producing CRE (CP-CRE) versus noncarbapenemase-producing carbapenem-resistant Enterobacteriaceae (Non-CP-CRE) in
four hospitals of a large healthcare system in Miami-Dade County and the experience
using an internal registry for patients carrying CRE .
Methods
Setting
This was a retrospective cohort study of patients admitted to hospitals of a large
health care system in Miami-Dade County between January 2012 and December 2016.
The health system has over 2,000 licensed beds; it is composed of four hospitals. Facility
A is a 1,100-bed major-teaching hospital with 134 adult intensive care unit (ICU) beds;
this facility is associated to the University of Miami, and it is also a national and
international referral center providing services in several specialties including one of the
largest transplant programs in the US. Facility B is a 358-bed community hospital with
62 ICU bed, that serves the northern area of the county; it receives admissions mainly
from surrounding long-term-care facilities (LTCF). Facility C is a 200-licensed bed
community hospital with 26 ICU beds and serves the southern area of the county; it
receives fewer admissions from nearby LTCF compared to Facility B. Lastly, Facility D
is a 325 licensed-bed major-teaching children hospital with 156 ICU beds, is associated
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to the University of Miami, and is a referral center offering a wide range of services
including transplant. This study was approved by the Institutional Review Board of
Florida International University.
Data collection
CRE cases were identified as part of the daily operation of the infection control
department and entered into a database. Only the first CRE isolate per patient in any
specimen source was included in the calculation of rates, this way each patient was
counted only once. Data were collected from the patient’s electronic medical record
(EMR) and the infection control automatic surveillance system (Vigilanz©). In addition,
the total number of Enterobacteriaceae tested against carbapenem and the number
reported as resistant were obtained from the automatic surveillance system.
Variable definitions
Carbapenem-resistant Enterobacteriaceae (CRE) were defined as
Enterobacteriaceae isolates reported resistant to any of the carbapenems listed by the
Clinical and Laboratory Standards Institute (CLSI) guidelines or that tested positive for
carbapenemase production from any specimen source.20 CRE cases were defined as
those where CRE carriage was identified via clinical or surveillance cultures.
Carbapenemase-producing CRE (CP-CRE) were defined as Enterobacteriaceae isolates
with carbapenemase detected by any method. Non-carbapenemase-producing
carbapenem-resistant Enterobacteriaceae (Non-CP-CRE) were those CRE with
carbapenemase test results reported as not detected. Cases were classified as communityonset if the specimen was collected ≤3 days after admission or hospital-onset if the
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specimen was collected >3 days after admission. Secondary outcomes included 30-day
mortality where day 1 was the day of the first positive CRE culture.19
Infection prevention interventions
In addition to the NHSN requirements for HAI surveillance, 20 beginning 2009,
surveillance for CRE has been in place at all the facilities within the healthcare system.
Rectal surveillance cultures and tracheal aspirates (ventilated patients) were collected on
admission/transfer to the ICUs and weekly thereafter in Facility A; this strategy was
expanded to the ICU of Facility B in 2014. Compliance with the surveillance culture
collection protocols was monitored as point prevalence at different points of the study
period. In 2010 a database for CRE was created and updated manually. In 2011 a new
electronic platform for infection control surveillance was made available to the
department; this platform was fed real-time with patient demographics and results from
the EMR via an interface and enabled automatically updates to the internal CRE
database.
In all the facilities, patients with CRE were placed on contact precautions for the
duration of their admission. If readmitted, patients with Non-CP-CRE were placed in
contact precautions for up to two years from the last positive culture; patients with CPCRE were placed in contact precautions in all readmissions. For each patient, the EMR
was tagged indicating that the patient needed contact precautions; this tagging was visible
in all pages of the EMR and was only discontinued by the Infection Control Department.
Contact precaution for CRE included private room setting, staff cohorting, use of gown
and gloves as per contact precautions. Compliance with isolation precautions was
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monitored by the Infection Control Department during daily rounds. Additionally, the
surveillance system was set up to alert the Infection Control Department about new CRE
isolates and known CRE cases readmissions. If carbapenemase production was detected,
the unit leadership hosting the patient was notified immediately via phone call and email
by the infection preventionist covering the unit, and cohorting of staff and patients was
initiated. Daily environmental disinfection was done using bleach-based products; from
2009 to 2014 environmental cleaning was routinely monitored using UV markers as
previously described.21 In August 2014, in response to an increased number of CP-CRE
cases, the infection control department started emailing the daily list of all CP-CRE
patients currently in the facility to bed placement, nursing unit leadership, environmental
services, antimicrobial stewardship, and respiratory therapy to facilitate patient and staff
cohorting.
In early 2015, Facility A experienced an outbreak of Klebsiella pneumoniae
carbapenemase (KPC)–producing Citrobacter freundii in one of its ICUs. As previously
reported, in response to the outbreak, the staff of the ICU received infection prevention
education; at the same time, the unit went into plumbing repairs.13 In addition to the
above-mentioned interventions, the system participated in the FL-DOH CRE initiatives,
which provided education and expert support.
Microbiology testing
Surveillance cultures for CRE were performed by perirectal swab or tracheal
aspirate sample cultured on a MacConkey plate with meropenem and ertapenem disks
followed by full identification and susceptibility testing as previously described.12 CRE
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isolates were routinely frozen for long-term storage. Identification and susceptibility
testing for clinical and surveillance cultures were performed using Vitek2 and confirmed
by E-test; if deemed resistant to any carbapenem, the isolate was further tested for
carbapenemase production. There were no changes in the methodology for antimicrobial
susceptibility testing during the study period. From 2012 to 2014 carbapenemase
production was tested using the Modified-Hodge-test; starting in 2015 carbapenemase
test was done using CarbaNP test.22 No further testing was routinely performed. In
addition, the isolates associated with the KPC-Citrobacter outbreak in 2015 were sent to
the University of Pittsburgh for molecular testing,13 and the frozen isolates underwent
further molecular testing later as part of this study.
Molecular testing
Crude DNA was prepared by the boiling method and used as the template for
polymerase chain reaction (PCR). Multiplex PCR was performed to detect blaKPC,
blaNDM, blaOXA-48, as described previously.23 For S. marcescens, a separate PCR was
performed to detect blaSME, also as previously described.24
Pulsed-field gel electrophoresis (PFGE) analysis was performed using restriction
enzyme XbaI (New England Biolabs, Ipswich, MA) and a CHEF III DR electrophoresis
system (Bio-Rad, Hercules, CA). The relatedness of PFGE patterns was determined by
the unweighted-pair group method using average linkages and cluster analysis with the
Dice setting on Bionumerics software (Applied Maths, Sint-Martens-Latem, Belgium).
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Statistical analysis
Facility-specific rates were calculated following the CDC definitions: Incidence density
rate was calculated dividing the number of new hospital-onset cases by total number of
patient- days and multiplying by 10,000. Admission prevalence was obtained dividing the
number of CRE community-onset events by the number of patient admissions and
multiplying by 100. Overall admission prevalence was calculated dividing the number of
first CRE cases (regardless of time spent in the facility) by the number of patient
admissions and multiplying by 100. Percent of CRE was calculated by dividing the total
number CRE by the number of Enterobacteriaceae tested for carbapenem susceptibility
and multiplying by 100.20
Non-CP-CRE and CP-CRE subgroups and rates were compared using t-tests for
continuous measures and χ2 or the Fisher exact test for categorical measures. Statistical
analyses were conducted using SPSS version 26 software (IBM, Armonk, NY). P-values
<0.05 were considered statistically significant.
Results
Demographics
From 2012 to 2016, a total of 371 unique CRE cases were identified. Of these,
160 (43%) had Non-CP-CRE, 150 (40%) had CP-CRE, and 61 (16%) were not tested for
carbapenemase production (Table 1). The largest proportion of cases was among males
(58%), Black/Non-Hispanics (45%) followed by White/Hispanics (34%), and among
patients ≥ 65 years old (46%). Mortality within 30 days after identification of the first
CRE isolate was 21%. There was no significant difference in the crude mortality rate at
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30 days (P = 0.51) between CP-CRE and Non-CP-CRE cases. Overall, 280 cases were
hospital-onset (75%) and 91 were community-onset (25%). An examination of the 91
community-onset cases revealed that all had previous exposures to healthcare-facilities;
furthermore, 17 (19%) were transferred from a hospital in South-Florida not associated
with our health system, 33 (36%) were transferred from LTCF, 33 (36%) were admitted
from their homes but had previous exposures to healthcare-facilities in the previous 6
months, and 8 (9%) were international patients from Nicaragua, Ecuador, Bahamas, Iran,
and Turkey.
Microbiology
The most frequent source for CRE was urine (32%) followed by respiratory tract
(29%) [Table1]. Only 16% of CRE cases were detected first by rectal surveillance
cultures. Klebsiella pneumoniae and Enterobacter cloacae were the most frequent CRE
species identified, 50% and 14% respectively. Out of the 371 cases, 30 patients had more
than one CRE species isolated with a maximum of 4 different species in one particular
patient; these were collected in most cases from the same sources during the same
admission. In total 132 CRE isolates were available for molecular testing; of those, 93
were positive by PCR for carbapenemase gene detection. The blaKPC gene was detected
in 84 (90%) of the isolates. Five (5%) of the isolates were positive for blaNDM (New Delhi
Metallo-β-lactamase); three of them were from international patients or recent travelers to
Turkey,25 Cuba, and the Bahamas; the other two cases were local patients. Most of the
first isolates per case were resistant to piperacillin-tazobactam (96%), aztreonam (96%),
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cefazolin (97%), ceftriaxone (91%), and meropenem (92%) but susceptible to amikacin
(87%) (Table 2).
During the study period, 47,963 Enterobacteriaceae isolates were tested against
any of the carbapenems from all hospitals; 2.0% were reported as resistant to at least one
carbapenem. (Table 3).
Rates of CRE
From 2012 to 2016, our health system had 484,602 patient admissions
contributing 1,922,425 patient days. Overall prevalence, admission prevalence, and
incidence density rate did not change significantly at the end of the study compared to
2012. The overall prevalence of CRE for all facilities combined was 0.077 cases per 100
patient admissions (95% confidence interval [CI], 0.069 – 0.085); the overall prevalence
for Facility A was twice that of the three other facilities combined, while facility C had
the lowest one for the system (Table 4). The CRE admission prevalence of all facilities
combined was 0.019 per 100 patient admissions (95% CI, 0.015 - 0.023). The CRE
incidence density of all facilities was 1.46 per 10,000 patient days (95% CI, 1.29 – 1.64).
Facilities A and B had more than twice the incidence density than facilities C and D. The
incidence density for CR-KP was 7.69 per 10,000 patient days (95% CI, 6.5 – 9.0); this
result was significantly higher than the one found for the state during the 2014 FL-DOH
collaborative of 0.47 per 10,000 patient-days (P = 0.003).
The overall prevalence and incidence density increased from 2012 to 2014 and
then declined from 2015 to 2016; the maximum peaks were between March 2015 and
June 2015 (Figure 1). These peaks were driven by a polyclonal cluster of KPC-producing
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Klebsiella pneumoniae and a KPC-producing Citrobacter outbreak in Facility A.13 The
introduction of active surveillance testing in Facility B in 2014 was also responsible for
the apparent increase of the incidence density in 2014 (Figures 1 and 2). The admission
prevalence in Facilities A and B increased over the study period, even though the
difference between the prevalence in 2012 compared to that of 2016 was not statistically
significant (P = 0.7). During the study period, there were in total of 33,737 admissions to
the units collecting surveillance cultures; 25,290 of them were screened at least once
during the ICU admission (75% compliance).
Discussion
We describe the epidemiology of CRE within a large healthcare system in MiamiDade County. In this cohort, we found similar distributions of the CRE isolates for
source, species, and mechanisms of resistance as those previously reported in other
highly populated areas of the US being Klebsiella pneumoniae the most frequent CRE
found and urine the most common source. 3,5,14,26 Previous to our study, there were no
data available about CRE rates among the Miami-Dade population. We believe this
information is important when considering allocating resources at the regional level for
CRE prevention as part of the CDC’s HAI Prevention Program and providing a baseline
for future strategic planning. Miami-Dade County is one of the most populated counties
in the US and a port of entry for immigrants, visitors, and international patients from
areas with endemic CRE.8,18, 24
The incidence of CRE in our facilities steadily increased during the first three
years of the study. Nevertheless, after implementing several interventions aimed at
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increasing early detection of cases, compliance with contact precautions, and
environmental disinfection, the rates rapidly decreased to levels lower than at the
beginning of the study. Early detection of cases by screening cultures of ICU patients and
the use of an internal registry integrated with our surveillance system and EMR enabled
rapid identification of new cases and readmissions. This information remained available
across different admissions and transfers among in-network facilities. At the same time,
tagging the EMR facilitated immediate initiation of specific precautions for CRE cases
particularly among readmissions.
Our study shows that CRE is still uncommon in the pediatric and the communityhospital population in the southern area of the healthcare system. This is probably
because the patients at these two facilities generally do not present from LTCF and do not
have previous exposures to other healthcare-facilities. Furthermore, we did not identify
any community-associated cases without known risk factors for CRE; all communityonset cases had previous exposures to healthcare-facilities or recent international travel.
This finding suggests that during the study period, in Miami-Dade, CRE was confined to
healthcare settings and was not spread in the community as has been document in other
areas such as North Carolina, South Carolina, Virginia, India, Spain, and Argentina.27
After performing molecular testing on the saved isolates, we found five cases
associated with CP-CRE harboring blaNDM.. Three of these cases were unnoticed during
the patients’ admissions, and they were “assumed” to be KPC producers as we did not
have molecular diagnostics available. Not knowing the specific mechanism of
carbapenemase production has serious implications for antimicrobial stewardship as the
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treatment might be inappropriate based on the spectrum of activity of each agent and the
need for combination therapy for metallo-β-lactamases. 28
The study found an incidence density of CR-KP notably higher than the one
found among participating facilities in the 2014 FL-DOH CRE collaborative (7.69 vs
0.47 cases per 10,000 patient days). Different from the FL-DOH collaborative, our study
included surveillance cultures instead of relying exclusively on clinical cultures; relying
only on clinical cultures reveals only the “tip of the iceberg” excluding the potential
threat of CRE spread by cases. Recent studies have highlighted the importance of
detecting cases to reduce the burden of CRE.29 One strategy to increase detection of cases
is to perform surveillance cultures in patients with known risk factors. According to a
model recently developed by Bartsch et al. to explore the impact of increasing CRE
carriers detection,29 we estimate that 5.74 new cases were prevented by active
surveillance testing by the end of 2016. This is taking into account that in 2016 active
surveillance testing was already in place for 7 years, and we detected 1 out of 6 of the
cases first by surveillance culture. In 2014 we expanded active surveillance testing and
also increased the effectiveness of contact precautions using daily email notification to
key personnel and education.
This study has several limitations. Not all patients were screened upon admission
to the facility. Therefore, there is a possibility that some cases classified as hospital-onset
were colonized on admission but only detected later during their admission and
misclassified as hospital-onset. There is also the possibility that they were undetected
because surveillance cultures were only done in the ICUs of the two larger facilities.
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Furthermore, the screening method used was not highly sensitive, and compliance with
surveillance cultures in the ICUs was only 75%. Screening every patient by culture upon
admission in a system as large as ours would be costly; moreover, only screening ICU
patients leaves out a large population of patients with known risk factors present on
admission that are not admitted to the ICU. Hospitals considering implementing active
surveillance cultures should take into consideration their influx of patients with risk
factors for CRE who are not admitted to the ICU.
Unfortunately, our registry has the limitation of only being available to our
network of facilities, and communication of CRE status to and from out-of-network
facilities relied on manual documentation and was subject to human error. Recent reports
indicate that the use of regional registries is effective in controlling the spread of
CRE.18,30,31 In our case, the internal registry played an important role in controlling the
initially increasing CRE rates. Having a county-wide or state-wide registry would have a
greater impact in the regional efforts to control the spread of CRE.31 We urge state and
local public health authorities to implement a regional registry to facilitate timely,
accurate communication between healthcare facilities to ensure that when a patient with a
history of highly drug-resistant organisms is admitted, prompt, appropriate infection
prevention practices and targeted antimicrobial stewardship management can be
implemented. In addition, it is important to differentiate CP-CREs vs non-CP-CREs as
the mechanism of resistance and transmission are different, and hospitals need to cohort
patients appropriately. Facilities with a similar prevalence of CRE as our institutions
should consider routine testing of carbapenemase types to determine the specific
mechanism of carbapenemase production taking advantage of available technologies.
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Conclusion
In conclusion, our study demonstrated that the burden of CRE in our population of
patients from Miami-Dade is similar to that of other highly populated cities in the US.
Rising rates of CRE can be controlled by infection prevention strategies supported by
tools such as registries and testing that allow rapid detection of carries and early
interventions.
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Table 1. Patient with CRE characteristics in a large healthcare system in Miami-Dade County;
2012 - 2016.
Non-CPCRE
CP-CRE
All CRE
CRE
CPUnk
n= 150
n= 371
n= 160
n=61
Gender
Male
88 (55%)
86 (57%)
43 (70%)
217 (58%)
Female
72 (45)
64 (43%)
18 (30%)
154 (41%)
Age (years)
≤ 17
14 (9%)
6 (4%)
4 (7%)
24 (6%)
18-44
21 (13%)
32 (21%)
11 (18%)
64 (17%)
45-64
52 (33%)
45 (30%)
16 (26%)
113 (30%)
≥ 65
73 (46%)
67 (45%)
30 (49%)
170 (46%)
Race/ethnicity
White/Hispanic
51 (32%)
52 (35%)
22 (36%)
125 (34%)
White/Non-Hispanic
47 (29%)
36 (24%)
9 (15%)
92 (25%)
Black/Hispanic
4 (3%)
3 (2%)
1 (2%)
8 (2%)
Black/Non-Hispanic
53 (33%)
50 (33)
28 (46%)
131 (35%)
Other
0 (2%)
5 (3%)
1 (2%)
6 (2%)
Unknown
5 (3%)
4 (3%)
0 (0%)
9 (2%)
LOS days, median (IQR)
37 (65)
48 (79)
44 (80)
48 (79)
LOS to onset days, median (IQR)
16 (24)
18 (38)
13 (42)
19 (40)
Facility
A -Major-teaching
106 (66%) 117 (78%) 27 (44%)
250 (67%)
hospital
B - Community
33 (21%)
20 (13%)
25 (41%)
78 (21%)
hospital
C - Community
5 (3%)
7 (5%)
5 (8%)
17 (5%)
hospital
D - Major-teaching
16 (10%)
6 (4%)
4 (7%)
26 (7%)
children hospital
Mechanism of
KPC
N/A
84 (90%)
N/A
84 (90%)
resistance
NDM
N/A
5 (5%)
N/A
5 (5%)
30

2 pvalue
0.1052

0.3662

0.2804

0.2800
0.2100

<0.001

n/a

OXA-48
N/A
1 (1%)
N/A
1 (1%)
SME
N/A
3 (3%)
N/A
3 (3%)
Onset
HO
125 (78%) 116 (77%) 22 (36%)
280 (75%)
0.0712
CO
35 (22%)
34 (23%)
39 (64%)
91 (25%)
Organism
Klebsiella pneumoniae
81 (51%)
90 (60%)
16 (26%)
187 (50%)
Enterobacter cloacae
29 (18%)
15 (10%)
8 (13%)
52 (14%)
Escherichia coli
22 (14%)
13 (9%)
11 (18%)
46 (12%)
Enterobacter
9 (6%)
6 (4%)
5 (8%)
20 (5%)
aerogenes
0.0001
Serratia marcescens
6 (4%)
8 (5%)
6 (10%)
20 (5%)
Citrobacter freundii
2 (1%)
9 (6%)
2 (3%)
13 (4%)
Proteus mirabilis
4 (2%)
0 (0%)
5 (8%)
9 (2%)
Other
7 (4%)
7 (5%)
8 (13%)
22 (6%)
Source
Surveillance culture
35 (22%)
25 (17%)
1 (2%)
61 (16%)
rectal
Surveillance culture
0 (0%)
3 (2%)
0 (0%)
3 (0.8%)
tracheal asp
Urine
49 (31%)
44 (29%)
25 (41%)
118 (32%)
0.0818
Respiratory (clinical)
41 (26)
44 (29%)
24 (39%)
109 (29%)
Blood
13 (8%)
14 (9%)
4 (7%)
31 (8.3%)
Wound/drain
10 (6%)
11 (7%)
4 (7%)
25 (7%)
Other
12 (8%)
9 (6%)
3 (5%)
24 ( 6%)
Expired within 30 days from first CRE
38 (24%)
31 (21%)
10 (16%)
79 (21%)
0.4759
isolate
CRE carbapenem resistant Enterobacteriaceae; Non-CP Carbapenem resistant Enterobacteriaceae notcarbapenemase producer; CP-CRE, carbapenemase-producer carbapenem-resistant Enterobacteriaceae; CRE
CPUnk, carbapenem resistant Enterobacteriaceae not tested for carbapenemase; LOS, length of stay; IQR,
interquartile range; KPC, Klebsiella pneumoniae carbapenemase; NDM, New Delhi metallo-β-lactamase; OXA48, oxacillynase-48; SME, Serratia marcescens enzyme; CO, community onset; HO, hospital onset.
31

Table 2. Susceptibility Profiles of Carbapenem-Resistant Enterobacteriaceae Isolates in a large healthcare system in
Miami-Dade County, 2012-2016.
Number of isolates (%)
Non-CP-CRE
CP-CRE
All CRE
S
I
R
S
I
R
S
I
R
Pip-Tazo
4 (3)
2 (2)
111 (95)
0 (0)
0 (0)
108(100)
6 (2)
4 (2)
245 (96)
Aztreonam
2 (8)
0 (0)
22 (92)
0 (0)
0 (0)
14 (100)
2 (4)
0 (0)
44 (96)
Cefazolin
1 (1)
0 (0)
90 (99)
0 (0)
0 (0)
79 (100)
7 (3)
0 (0)
213 (97)
Cefepime
5 (20)
2 (8)
18 (72)
5 (22)
5 (22)
13 (57)
24 (34)
8 (11)
39 (55)
Ceftazidime
11 (7)
3 (2)
142 (91)
6 (4)
7 (5)
131 (91)
31 (9)
14 (4)
316 (88)
Ceftriaxone
8 (5)
0 (0)
149 (95)
4 (3)
0 (0)
141 (97)
29 (8)
3 (1)
331 (91)
Ciprofloxacin
12 (48)
3 (12)
10 (40)
4 (20)
0 (0)
16 (80)
28 (42)
3 (5)
35 (53)
Levofloxacin
50 (32)
10 (6)
98 (62)
38 (26)
14 (10)
94(64)
112(31)
29 (8)
224 (61)
Meropenem
1 (0.6)
4 (2.5) 154 (96.9)
0 (0)
2 (1)
144 (99)
0 (0)
28 (8)
338 (92)
Amikacin
139 (88)
2 (1)
17 (11)
123 (84)
1 (1)
22 (15)
319 (87)
5 (1)
41 (11)
Gentamicin
87 (55)
6 (4)
64 (41)
72 (49)
12 (8)
62 (42)
197 (54)
22 (6)
145 (40)
Tobramycin
72 (46)
15 (9)
71 (45)
37 (25)
25 (17)
84 (58)
145 (40)
47 (13) 173 (47)
Trimethoprim
62 (39)
0 (0)
95 (61)
50 (34)
0 (0)
95 (66)
137 (38)
0 (0)
225 (62)
Tetracycline
58 (37)
14 (9)
85 (54)
65 (45)
14 (10)
66 (46)
145 (40)
35 (10) 181 (50)
Non-CP-CRE, Non carbapenemase-producer carbapenem-resistant Enterobacteriaceae; CP-CRE, Carbapenemase-producer
carbapenem resistant Enterobacteriaceae; All CRE includes isolates tested and not tested for carbapenemase production; S,
susceptible; I, intermediate; R, resistant, Pip-Tazo, piperacillin- tazobactam.
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Table 3. Percent of carbapenem-resistant Enterobacteriaceae, in a
large healthcare system in Miami-Dade County, 2012-2016.
CRE TOTAL
%
tested
All Enterobacteriaceae

946

47,963

1.97

Klebsiella pneumoniae

487

9,922

4.91

Escherichia coli

151

23,151

0.65

Enterobacter sp

102

3,854

2.65

CRE carbapenem resistant Enterobacteriaceae
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Table 4. Carbapenem resistant Enterobacteriaceae rates by facility of a large
healthcare system in Miami-Dade County, 2012-2016.
CRE overall
prevalence rate
(number of first
CRE event per
100 admissions)

CRE admission
prevalence
(number of
community-onset
cases per 100
admissions)

CRE incidence
density rate
(number of
hospital-onset per
10,000 patient
days)

Facility A Majorteaching hospital

0.307

0.057

1.93

Facility B
Community
hospital

0.108

0.043

1.60

Facility C
Community
hospital

0.007

0.003

0.41

Facility D Majorteaching children
hospital

0.035

0.008

0.56

All facilities

0.077

0.019

1.46

CRE, Carbapenem resistant Enterobacteriaceae; Overall prevalence = 1st
CRE event /patient admissions x 100; Admission prevalence = number of
community-onset events/patient admission x 100; Incidence density rate:
number of hospital-onset cases/patient days x 10,000.
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Figure 1. Prevalence and Incidence Rates by quarter for all facilities combined in a
large healthcare system in Miami-Dade County, 2012-2016.

CRE carbapenem-resistant Enterobacteriaceae; FLDOH Florida Department of Health;
AST active surveillance testing; CP-CRE carbapenemase producer Enterobacteriaceae;
SICU surgical intensive care unit.
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Figure 2. Carbapenem Resistant Enterobacteriaceae rates by facility in a large healthcare
system in Miami-Dade County, 2012-2016

CRE, Carbapenem resistant Enterobacteriaceae; FLDOH, Florida Department of Health;
AST active surveillance testing; SICU surgical intensive care unit; Overall prevalence
rate = 1st CRE event /patient admissions x 100; admission prevalence rate = number of
community onset events/patient admission x 100; Incidence density rate: number of
hospital onset cases/patient days x 10,000.
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Risk factors for the development of infections associated with carbapenemaseproducing Enterobacteriaceae among previously colonized patients: a retrospective
cohort study

Abstract
Not all patients who acquire Carbapenemase-producing Enterobacteriaceae (CPE)
develop infections by these organisms; many remain only colonized. Out of 54 CPEcolonized patients, 16 (30%) developed CPE infections. We identified indwelling urinary
catheter exposure, exposure to intravenous colistin, and overseas transfer as variables
associated with CPE infection development among colonized patients.

Background

Carbapenemase-producing Enterobacteriaceae (CPE) have spread globally and
are considered urgent public health threats due to the increasing number of infections,
limited options from treatment, and high mortality.1,2 Carbapenemase production is an
important mechanism of carbapenem resistance that contributes to the spreading of CPE
since it is frequently plasmid-mediated and can be transferred among different species of
Enterobacteriaceae.1 Risk factors for CPE infection include residence in long-term-care
facilities, use of medical devices, antibiotic exposures, and prior colonization with CPE.
1,3
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Not all CPE-colonized individuals develop CPE infection.3,4 There are limited
reports in the US describing factors associated with CPE infection after colonization;
most studies are limited to rectal colonization while colonization of other body sites and
associated infection has not been often studied.4 We aimed to identify patient
characteristics associated with CPE infections among patients previously colonized by
the same organism.
Methods
This was a retrospective cohort study of CPE-colonized patients admitted to any
of four hospitals in a large healthcare system (three adult and one pediatric, 2,500-beds)
in Miami, Florida between 2012-2016. The study was approved by the Florida
International University Institutional Review Board.
Rectal and tracheal aspirate (ventilated patients) surveillance cultures were
collected on admission to adult intensive care units (ICU) and weekly thereafter until
discharge/transfer out of the ICU. Surveillance cultures were processed in MacConkey
plates following standard protocol (Supplementary material).
We included patients colonized at the time of first CPE identification; patients
with first CPE isolated from a normally sterile source were excluded. Patients with first
CPE isolated from a non-sterile source were evaluated for infection vs. colonization at the
time of first identification; infections were defined using the National Healthcare Safety
Network (NHSN) protocols5 and review of infectious disease consultation and medical
record. Colonized patients were followed through subsequent admissions for
development of infection or censored. The probability of information bias by case
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misclassification was reduced by reviewing every case by an infection disease physician
and by infection preventionists during patient’s admission and again retrospectively for
the purposed of the study. Data were collected retrospectively from the electronic
medical record and infection prevention database from the date CPE was first detected
until the date of event of infection or censoring.
Baseline characteristics were compared using χ2 or t-test. Kaplan-Meier was used
to analyze the probability of developing CPE infections after colonization over time. Cox
proportional hazards regression models were used to assess the association between
predictors and the development of CPE infection. Statistical analysis was performed
using SPSS 26 software (IBM, Armonk, NY).
Results
In total, 152 patients with CPE were identified during the study period; 98 were
excluded, resulting in 54 (35%) included in the analysis (Supplementary Figure 1). Of the
54 colonized patients, 34 (80%) had Klebsiella pneumoniae (Table 1). Thirty-five isolates
were tested by PCR; of those, 91% were positive for blaKPC, and 9% for blaSME. The most
frequent source of colonization was rectal (41%), then urinary (35%), and respiratory
(24%). Sixteen (30%) of the colonized patients developed CPE infection. Patient
characteristics for both groups are presented in Table 1. Two (12%) patients had
infections in three different body sites, eight (50%) had infections in two different body
sites, and six (38%) had infection in one body site, yielding a total of 28 infections. The
most frequent type of infections was bloodstream infections (39%), followed by
pneumonia (32%), and urinary tract infections (18%) (Supplementary Table 1).
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CPE-colonized patients were followed up for a mean of 304 days (IQR, 422). The
mean time for infection development was 63 days (IQR=81; Range 0-7 months). KaplanMaier curve analysis (Supplementary Figure 2) showed that the probability of
development CPE-related infections among colonized patients decreased over time, with
a higher probability in the first three months after the identification of colonization.
After adjusting for significant variables in the multivariable Cox regression
(Supplementary Table 2), CPE-colonized patients with indwelling urinary catheter (IUC)
exposure (adjusted-Hazard Ratio [aHR] 4.4; P-value 0.034), exposure to colistin (aHR
3.17; P-value 0.037), or transferred from overseas (aHR 9.77; P-value 0.021) had a
higher hazard of developing CPE infections (Table 2). Evaluation of those exposed to
colistin showed that patients who developed CPE infection were exposed via intravenous
route while those exposed to inhaled colistin did not; colistin was administered for
treatment of extensively-drug-resistant (XDR) Pseudomonas, Acinetobacter, or
Stenotrophomonas.
Discussion
We identified the use of indwelling urinary catheter (IUC) exposure to
intravenous colistin, and transfer from overseas facilities as variables associated with the
development of CPE infection. All infections occurred within 7 months of being
identified as CPE colonized; the probability of developing CPE infections decreased over
time possibly related to spontaneous colonization clearance.
Our findings are consistent with previous reports that identified CPE colonization
as a risk factor for the development of CPE-related infections.4,6 These studies focused on
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rectal colonization. This study included other sources of colonization, finding that a
higher percentage of those colonized in the respiratory tract developed infection although
the difference was not statistically significant. Nevertheless, this finding highlights the
importance of considering screening more than one anatomical site. Also, facilities
should consider including in their CPE surveillance testing high-risk populations such as
patients transferred from overseas.
In our cohort, 30% of the colonized patients developed CPE infections; this has
implications for antibiotic selection. Colistin resurged as an option of treatment of XDRPseudomonas, Acinetobacter, and Enterobacteriaceae infections.7 Until recently, there
was no consensus about dosage and use of colistin for such infections or about
antimicrobial susceptibility testing and breakpoints.7 The possibility that resistance to
colistin played a role in the development of the CPE infections among our cohort is
unknown due to lack of reliable testing at the time of the study. Pseudomonas and
Acinetobacter were tested against colistin by Etest; the reliability of this method has been
largely questioned.8 Recently, there has been an increasing number of reports related to
colistin resistance; the mechanisms of colistin resistance are not yet fully understood.9
Antimicrobial stewardship programs should tailor interventions to align with the recent
recommendations for the use of colistin and recently available antimicrobials.
IUC are among the most commonly utilized devices in hospitals. 10 We found that
exposure of these devices was associated with an increased probability of developing
CPE infections in colonized patients; this finding concurs with previous reports.3
Infection prevention interventions should aim to reduce the utilization of such devices
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preventing catheter-associated urinary tract infections (CAUTI) as well as CPE
infections.
This study has several limitations. First, the small sample size reduced the power
to detect other possible associations. Second, active surveillance cultures were only
collected from adult-ICU patients; among non-ICU patients, detection of colonization
relied on the identification of CPE in clinical cultures, introducing selection bias and
possibly information bias affecting the results and limiting generalizability of the study.
Third, 91% of the isolates tested had blaKPC as the resistance mechanism, facilities with
higher prevalence of other carbapenemases might have different findings; further studies
should explore this probability. Lastly, we introduced time-dependent bias by measuring
exposure to devices and to antibiotics as categorical variables and possibly affecting the
HR.
In conclusion, 30% of CPE-colonized patients developed infections associated
with these organisms. We suggest reducing the use of IUC for patients colonized with
CPE and implementing the use of alternative devices such as condom catheters or
external female urinary catheters whenever possible. Furthermore, we suggest expanding
CPE surveillance testing including other anatomical sources in addition to the rectum.
Lastly, we recommend limiting the use of colistin among CPE-colonized patients to
decrease the risk of infection as part of multidisciplinary interventions. Further studies
should evaluate the effect of interventions such as selective decolonization, or fecal
transplantation, to prevent the CPE infections among colonized patients.
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Table 1. Characteristics of patients colonized with Carbapenemase-producing
Enterobactericeae (CPE) at a large health care system, 2012-2016
No CPE
Infection
N= 38 (%)

CPE
Infection
N= 16 (%)

P-value

Male

27 (71)

8 (50)

Female

11 (29)

8 (50)

Age, mean (± SD)
Admission
Home
source when
Other hospital
first identified
LTCF
as colonized
Overseas
with CPE
Solid organ transplant
Immunocompromised
Steroids > 2 weeks
Surgery
Endoscopy
ICU admission
Charlson score, mean (± SD)
DM with end-organ
damage
Congestive heart failure
Myocardial infarction
Peripheral vascular disease
Chronic kidney disease
Cardiovascular disease
Comorbidities Dementia
COPD
Connective tissue disease
Pepcid ulcer
Moderate to severe liver
disease
Metastatic solid tumor
AIDS
Central venous catheter
Indwelling urinary catheter (IUC)
Ventilator
Klebsiella pneumoniae
Organism
Enterobacter spp

58 (25)
21(55)
7 (18)
7 (18)
3 (8)
10 (26)
12 (32)
5 (13)
25 (66)
8 (21)
32 (84)
4.5 (2.5)

63 (13)
3 (19)
7(44)
4 (25)
2 (12)
6 (37)
7 (44)
6 (37)
13 (81)
2 (12)
14 (87)
5.7 (2.9)

0.467

6 (16)

3 (19)

0.496

1 (3)
3 (8)
4 (10)
12 (32)
3 (8)
0 (0)
4 (10)
1 (3)
1 (3)

3 (19)
2 (12)
2 (12)
5 (31)
2 (12)
2 (12)
2 (12)
0 (0)
0 (0)

*0.039
0.594
0.833
0.981
0.594
*0.026
0.833
0.512
0.512

8 (21)

4 (25)

0.271

0 (0)
1 (3)
26 (68)
19 (50)
17 (45)
23 (60)
8 (21)

1 (6)
1 (6)
13 (81)
13 (81)
11 (69)
11 (69)
1 (6)

0.162
0.52
0.337
*0.041
0.06

Gender

45

0.139

0.084

0.411
0.178
0.450
0.256
0.460
0.756
0.148

0.754

Colonization
site

Escherichia coli
Serratia marcescens

2 (5)
2 (5)

1 (6)
1 (6)

Citrobacter sp.

3 (8)

2(12)

Rectal
Urine

16 (42)
14 (37)

6 (38)
5 (31)

Respiratory

8 (21)

5 (31)

35 (92)

15 (94)

< 4 days
4-7 days
8-18 days

6 (16)
7 (18)
5 (13)

1 (6)
1 (6)
3 (19)

> 18 days

20 (53)

11 (69)

None
1
2
3-4

3 (8)
3 (8)
1 (3)
15 (40)

1 (6)
1 (6)
1 (6)
1 (6)

>4

16 (42)

12 (75)

Antibiotic exposure***
Antibiotic
days***

Number of
antibiotics***

0.724
0.833

0.446

0.135

Aminoglycosides
10 (26)
7 (44)
0.208
1st -2nd gen cephalosporins
2 (5)
0 (0)
0.350
3rd- 4th gen cephalosporins
25 (66)
11 (69)
0.833
Carbapenem
18 (47)
11 (69)
0.150
Daptomycin
1 (3)
3 (19)
*0.039
Vancomycin
23 (60)
13 (81)
0.140
Antibiotic
class***
Quinolones
12 (32)
16 (100)
*0.035
Metronidazole
10 (26)
9 (56)
*0.035
Sulfas
11 (29)
7 (44)
0.292
Colistin
6 (16)
7 (44)
*0.028
Penicillins
11 (29)
4 (25)
0.767
Other
24 (63)
11 (69)
0.777
All cause death within 30-days of
8 (21)
6 (38)
0.208
colonization detection.
All cause overall death after colonization
13(34)
10 (62)
0.055
detection.
CPE= Carbapenemase-producing Enterobacteriaceae; SD = standard deviation;
LTCF= long-term-care facility; ICU =intensive care unit; DM= diabetes mellitus;
COPD= Chronic obstructive pulmonary disease; AIDS = Acquired immunodeficiency
syndrome; IUC= Indwelling urinary catheter
* P-value < 0.05
***Antibiotic exposures were measured since first identified as colonized until date of
event for infections, censoring date, or end of study period whichever occurred first.
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Table 2. Reduced model for CPE infection among colonized patients at a South
Florida Healthcare System 2012-2016.
Foley
Colistin
Admission source

aHR
4.4
3.17
ref
3.54
4.32
9.77

Home
Another hospital
LTCF
Overseas

95%CI
1.11-17.38
1.072-9.37
0.87-14.42
0.91-20.42
1.40-67.93

P-value
*0.034
*0.037
0.105
0.078
0.065
*0.021

* P-value ≤ 0.05
CPE= carbapenemase producing Enterobacteriaceae; aHR = Adjusted Hazard
ratio; CI = confidence interval; LTCF = Long-term-care facility.

Supplementary materials (Available only online)
Carbapenemase-producing Enterobacteriaceae cultures process description.
The surveillance samples were cultured on MacConkey agar plates with 10 µg
meropenem and ertapenem disks. Organism identification and full susceptibility testing
from surveillance and clinical isolates were performed using the Vitek2® system.
Carbapenemase production was tested phenotypically with the Modified Hodge Test until
2014 and using CarbaNP Test starting in 2015. Isolates were frozen for epidemiological
reasons. For the purpose of this study, viable isolates were tested by PCR in 2019 to
detect blaKPC, blaNDM, and blaOXA-48; Serratia marcescens isolates were also tested for
blaSME.
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Supplementary Table 1. CPE-infection types based on initial colonization source among
patients admitted to large healthcare system in Miami FL. 2012-2016.
Initial Colonization Source
Rectal
N=11
(%)

Respiratory
(%)

N=8

Urinary tract
N=9 (%)

Total Infections
N=28 (%)

BSI

3 (27)

3 (38)

4 (44)

10 (36)

UTI

2 (18)

1 (12)

2 (22)

5 (18)

PNU

4 (36)

4 (50)

0 (0)

8 (26)

SSI

1 (9)

0 (0)

0 (0)

1(4)

IAB

1 (9)

0 (0)

3 (33)

4 (14)

BSI= blood stream infections; UTI= urinary tract infections; PNU= pneumonia; SSI =
surgical site infection; IAB = Intrabdominal infection
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Supplementary Table 2. Cox proportional hazards ratios by predictors for CPE infection among
colonized patients at a large health care system in Miami, Florida 2012-2016
Bivariable regression

Gender

Female

Age, mean (± SD)
Admission
source

Home

HR

95% CI

P-value

0.67

0.25-1.78

0.418

1.01

0.99-1.04

0.252

ref

Multivariable regression
Full Model
aHR

0.710

ref

95% CI

P-value

0.24

Other hospital

5.21

1.33-20.35

**0.018

2.12

0.39-11.47

0.385

LTCF

3.95

0.87-17.88

*0.074

5.91

1.28-27.37

**0.039

Overseas

8.78

1.35-57.20

**0.023

14.85

1.43-53.80

**0.024

Solid organ transplant

1.12

0.41-3.12

0.821

Immunocompromised

1.43

0.53-3.82

0.480

Steroids > 2 weeks

2.48

0.90-6.83

*0.079

3.04

0.79-11.70

0.106

Surgery

1.41

0.40-4.97

0.589

Endoscopy

0.58

0.13-2.58

0.478

ICU admission

0.61

0.14-2.70

0.516

Charlson score

1.13

0.95-1.35

0.167

CVC

1.68

0.48-5.94

0.417

IUC

3.90

1.10-13.8

**0.035

5.94

1.28-27.37

**0.023

Ventilator

2.98

0.96-9.27

*0.059

1.19

0.28-5.09

0.814

Devices

Organism

Colonization site

Klebsiella
pneumoniae

ref

0.936

Enterobacter sp

0.46

0.06-3.61

0.464

Escherichia coli

1.05

0.13-8.15

0.963

Serratia
marcescens

1.3

0.29-5.89

0.733

Citrobacter sp.

1.35

0.17-10.53

0.775

Rectal

ref

Urine

1.08

0.678
0.33-3.54
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0.902

Respiratory
Antibiotic exposure
Antibiotic days

Number of
antibiotics

Antibiotic class

1.66

0.50-5.44

0.405

1.54

0.20-11.65

0.678

< 4 days

ref

4-7 days

1.42

0.09-22.77

0.804

8-18 days

5.45

0.56-53.18

0.145

> 18 days

2.63

0.34-20.43

0.355

None

0.419

ref

0.340

1

1.42

0.08922.86

0.802

2

3.98

0.24-64.81

0.332

3-4

0.31

0.019-4.93

0.405

>4

2.17

0.28-16.70

0.458

Aminoglycosides

1.58

0.59-4.25

0.364

3rd-4th gen ceph

1.12

0.39-3.22

0.839

Carbapenem

2.21

0.76-6.39

0.144

Vancomycin

3.00

0.85-10.60

*0.089

Quinolones

2.23

0.81-6.12

0.122

Metronidazole

3.00

1.10-8.17

**0.031

Sulfas

1.37

0.51-3.69

0.529

Colistin

2.76

1.02-7.42

**0.045

Penicillins

0.75

0.24-2.34

0.622

Other

1.19

0.41-3.42

0.752

1.32

0.25-6.91

0.744

1.04

0.25-4.39

0.955

3.13

0.85-11.50

0.086

* p-value <0.1
** p-value <0.05
CPE = Carbapenemase producing Enterobacteriaceae; HR= Hazard Ratio; aHR= Adjusted
Hazard Ratio; CI = confidence interval; SD= standard deviation; ref = reference ; LTCF = longterm-care facility; ICU= Internsive care unit; CVC= Central Venous Catheter; IUC= Indwelling
urinary catheter; 3rd-4th gen ceph= 3rd-th generation cephalosporins.
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Supplementary Figure 2. Kaplan-Meier curve for CPE-colonized patients hazard of
developing infections by CPE over
time.

CPE = Carbapenemase-producing Enterobacteriaceae.
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Duration of Carbapenemase-producing Enterobacteriaceae Carriage among
Hospitalized Patients in Miami, FL: a Retrospective Cohort Study.
Abstract
Background
Current recommendations by the Centers for Disease Control and Prevention (CDC)
suggest placing patients with carbapenem-producing Enterobacteriaceae (CPE) in contact
precautions (CP), but there is no consensus on the appropriate duration of precautions.
We aimed to evaluate predictors for prolonged CPE carriage and median clearance time.
Methods
Hospitalized patients with first isolated CPE identified from 2012 to 2016 were followed
for clearance of CPE using at least two rectal or tracheal aspirate surveillance cultures
and clinical cultures. Predictors associated with prolonged CPE carriage were assessed
using Cox proportional hazards.
Results
Out of 75 eligible patients, 25 (33%) cleared their CPE-carrier status; the median time to
clearance was 80 days (Range, 16–457). Patients who were immunocompromised, had
mechanical ventilation exposure, or exposure to carbapenems had 66%, 66%, and 86 %
(HR, 0.34, 0.34, and 0.14, respectively [P-value <0.05]) lower probability of clearing
their CPE carrier status compared to those immunocompetent or without such exposures.
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Patients with CPE isolated from more than one anatomical body site had a 5.3 times
higher probability of clearing their CPE-carrier status (P-value <0.001).
Conclusion
Patients immunocompromised, with mechanical ventilation exposure, or exposure to
carbapenems had higher risk for prolonged CPE carriage. Infection prevention programs
should consider these predictors as part of their assessment of discontinuing contact
precautions among CPE carriers to prevent horizontal transmission and outbreaks within
healthcare facilities.

Background
Since the first reports in the early 1990s, Carbapenem-resistant
Enterobacteriaceae (CRE) have spread across the world 1-3. CRE are a public health threat
globally due to their rapid spread, and limited treatment options. CRE can be resistant to
carbapenems by different mechanisms including production of carbapenemases 1,4-6.
Carbapenemase-producing Enterobacteriaceae (CPE) synthesize β-lactamases that
hydrilyze carbapenems, rendering the treatment with this class of antibiotics ineffective.
The Centers for Disease Control and Prevention (CDC) recommendations for
healthcare facilities to prevent and control the transmission of CPE include placing CPE
patients on contact precautions (CP), as well as cohorting patient and staff 7. These
recommendations do not provide guidance about when to discontinue CP. The few
studies that have assessed the duration of carriage of CPE have been conducted mainly
outside the US 8-15; thus, there is limited research on this topic in US healthcare settings.
In 2018, the Society for Healthcare Epidemiology of America (SHEA) published expert
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guidance regarding the duration of CP for acute-care facilities in the case of CPE 13. In
their systematic review, the authors found wide variability in the median time for CPE
clearance. Most of the studies included in the review were from Israel, China, or Europe.
They also reported that only 32% of the facilities in the US had policies allowing the
discontinuation of CP for CRE. Of those with policies, 28% reported using screening
tests for discontinuing CP, and 38% reported using a ‘greater than one year since the last
positive test’ rule to discontinue CP. The expert guidance recommends maintaining CP
indefinitely for extensively drug-resistant Enterobacteriaceae such as CPE 13. We
therefore aimed to evaluate the duration of CPE carriage and factors associated with its
prolonged carriage among patients admitted to the hospitals of the largest healthcare
system in Miami, FL.
Methods
This was a retrospective cohort study among patients admitted between January
2012 and December 2016 to any of the four hospitals of the health system. The system
comprises two community hospitals and two major referral tertiary-care teaching centers,
one adult and one pediatric. The system has over 2,000-licensed hospital beds and
includes several medical specialties including trauma, burns, one of the largest solid
organ transplant centers in the US, an 80-bed inpatient rehabilitation facility, two longterm care facilities, and numerous outpatient clinics. As previously described 16, all
patients admitted to adult ICUs were screened for CPE colonization. Rectal and tracheal
aspirate (ventilated patients) cultures were collected upon admission to the ICU and
weekly thereafter until discharge or transfer out of the ICU. The surveillance samples
were cultured on MacConkey agar plates with 10 µg meropenem and ertapenem disks
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after enrichment in Trypticase Soy Broth and meropenem disk. Organism identification
and susceptibility testing from surveillance and clinical isolates were performed using the
Vitek2® system. Carbapenemase production was tested with the Modified Hodge Test
until 2014 and using CarbaNP Test beginning in 2015. Isolates were routinely frozen for
later epidemiologic analysis. Viable isolates were sub-cultured and tested by PCR in
2019 to detect blaKPC, blaNDM, and blaOXA-48; Serratia marcescens isolates were also
tested for blaSME as previously described 5,17.
We included patients that had their first CPE detected in either surveillance or
clinical cultures and who also had two or more subsequent surveillance cultures collected
during admission to any of the facilities during the study period. Patients with their first
CPE isolated prior to the study period were excluded. We followed eligible patients from
the time they were first determined as CPE carriers until they were considered
cleared/censored, including subsequent admissions to any of the system facilities.
Patients with prolonged CPE carriage were censored when last seen in any of the system
facilities or at the end of the study period. A patient was considered CPE cleared when
he/she had two or more negative surveillance cultures from the initial source (rectal or
respiratory), and other CPE were not isolated from any other clinical cultures. If the first
CPE was identified in clinical culture, at least one negative culture had to be collected
from the same site. A patient was considered recurrent if after meeting clearance criteria,
a CPE was isolated from any culture. Patients were considered immunocompromised
based on CDC definition 18 which included: neutropenic, those with leukemia, lymphoma
or who are HIV positive with CD4 count <200 cells/µL, those who have undergone
splenectomy, history of solid organ or hematopoietic stem cell transplant, those on
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cytotoxic chemotherapy, on enterally or parenterally administered steroids (excluding
inhaled and topical steroids) daily for more than two weeks.
Data were collected retrospectively using the electronic medical record (Cerner
Corp©) and the Infection Prevention and Control Surveillance System platform (Vigilanz
Corp©). Antibiotic and device exposures were collected as categorical (yes/no) variables
at any time from first CPE isolation to clearance, censoring, or end of the study. The
study was approved by the Florida International University Institutional Review Board
and the health system’s Office of Research.
Baseline characteristics of the groups were compared based on clearance status
using χ2 and Fisher exact tests for proportions and Student t-tests for continuous
variables. Median carriage time was determined using the Kaplan-Meier curve. Factors
associated with a prolonged carriage were analyzed using Cox proportional survival
analysis 19. The assumption of proportionality was evaluated using survival curves for
each variable, and variables that violated the assumption were excluded 20. Bivariable and
multivariable Cox proportional hazards regression models were used to assess the
association between predictors and CPE clearance. We obtained hazard ratios and 95%
confidence intervals. Interactions between different antibiotic combinations frequently
used for CPE treatment at the time of the study were also evaluated as predictors for CPE
clearance. Multivariable Cox regression analyses included variables with P-value <0.1 in
bivariable analysis, and the backward stepwise procedure was used to select the best
model. The variables included in the multivariable analysis were assessed for
multicollinearity. Statistical analysis was performed using SPSS version 27 software
(IBM, Armonk, NY).
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Results
During the study period, there were 152 unique patients with their first CPE
identified through surveillance or clinical cultures across the four hospitals; of those, 75
(49.3%) patients met the study inclusion definition after 77 (50.6%) were excluded due to
the lack of more follow up surveillance cultures. Patients included in the final analysis
were followed for a median time of 83 days (IQR, 36–241 days) and a maximum of 1,754
days (58 months). Most patients had the first CPE isolated from urine (39%), followed by
respiratory tract (35%), and rectal (16%) (Table 1). The most frequent CPE identified
was Klebsiella spp. (61%), followed by Enterobacter spp. (15%). For carbapenemases
produced by CPE isolates, Klebsiella pneumoniae carbapenemase (KPC) accounted for
69% while New Delhi Metallo-β-lactamase (NDM) accounted for 4%. Fifty (67%)
patients had CPE isolated from more than one body site with a maximum of four sites.
The median time from first detection to last CPE positive culture was 24 days (Range, 0–
1,252). Eleven (15%) patients only had one CPE positive culture. Twenty-five (33%)
patients met the criteria for CPE clearance; the overall median time for clearance was 80
days (Range, 16–457). Of the 25 cleared patients, 15 (60%) cleared within 3 months, 19
(76%) within 6 months, 22 (88%) within one year, and all 25 by 15 months. Nineteen
(76%) of the patients were cleared within the same index admission with a median
length-of-stay of 69 days (Range 54-428 days). Recurrence was detected in 8 (32%) of
the cleared patients; the median time to recurrence was 40 days (Range, 10-671 days).
Baseline characteristics of groups based on clearance are presented in Table 1. There was
no statistically significant difference in mortality rates between the two groups.
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Bivariable Cox proportional regression showed crude hazard ratios with P-value <
0.1 for females, immunocompromised patients, exposure to mechanical ventilator,
exposure to carbapenems, and CPE isolated from more than 1 body site (Table 2).
Analysis of the effect of interactions between different classes of antibiotics and time to
clearance did not show any statistically significant associations. After adjusting for all
variables in the Cox proportional multivariable analysis model, immunocompromised
patients had a 66% (P-value, 0.014) lower probability of clearing CPE compared to
immunocompetent patients. Patients who experienced mechanical ventilator also had a
66% lower probability of clearance compared to those without such exposure (P-value,
0.016 ). Patients with exposure to carbapenems had a 86% lower probability of clearance
compared to those without exposure to carbapenems(P-value, 0.010). Interestingly,
patients with CPE isolated from more than one anatomical site had a 5.3 times higher
probability of CPE clearance than those who had CPE isolated from only 1 body site (Pvalue <0.001) (Table 3). A deeper look into the cleared patients who had CPE isolated
from more than one anatomical site revealed that 12 (86%) had CPE-related infections
and only 2 (14%) were deemed as colonized. Figure 1 shows the probabilities over time
of CPE clearance based on exposure to mechanical ventilator, exposure to carbapenems,
and being immunocompromised, or having CPE isolate from more than one body site.
Discussion
This study evaluated the duration of CPE carriage and determinants for prolonged
carriage among hospitalized patients. Patients had positive CPE cultures identified up to
42 months after the initial positive culture; only 33% of the patients met the criteria for
clearance within 15 months. We found that patients who were immunocompromised,
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exposed to mechanical ventilation or treated with carbapenems had a lower probability of
clearance of CPE. Remarkably, those patients that had CPE isolated from more than one
anatomical site had over 5 times the probability of achieving clearance compared to those
that only had CPE isolated from one body site; this finding perhaps represents instances
of effective therapy and source control of CPE-related infections because most of those
patients had systemic infections. Our institution does not utilize decolonization therapy
strategies for CPE carriers. Furthermore, during the study period, β-lactamase inhibitor
combinations were not widely available. Ceftazidime/avibactam (CZA) was approved in
mid-2015 for the treatment of complicated urinary tract infection or intraabdominal
infections 21. During the study period, treatment for CPE infections was tailored on a
case-by-case basis; CZA was used on a few occasions, mostly under compassionate use
near the end of the study. On the contrary, those patients who had CPE isolated only from
one body site were deemed to be colonized and thus did not receive therapy targeting
CPE.
Unfortunately, current CDC recommendations for control of CPE do not include
guidance on how long a patient, either colonized or infected, should remain on CP to
prevent horizontal transmission in acute care facilities,7 leaving it up to each facility to
determine how long to maintain CP for these patients during index admission and
subsequent readmissions. Placing patients on CP indefinitely with dedicated staff places
an extra burden on the facility. European recommendations establish a case-by-case
approach based on risk factors in consultation with the infection prevention team for
discontinuation of CP 22. Several studies have assessed the duration of CPE colonization;
most of these studies were from outside the US and relied only on the findings from
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rectal surveillance cultures 14,15,23,24. Moreover, previous studies have shown that
screening from more than one anatomical site increases the chances of detecting CPE 25.
In our cohort, we found that 21 of the cases never demonstrated positive results in rectal
surveillance cultures but did show positive results from respiratory specimens. Criteria
for discontinuation of CP should include CPE negative cultures concordant with the
anatomical site from where CPE was previously isolated and more than one negative
screening culture. Furthermore, our study identified findings similar to other studies with
a median time to clearance greater that 60 days and findings of CPE long-term carriage
for longer than three years 26. This finding is important to consider when using the caseby-case approach recommended in European guidelines, particularly in subsequent
readmissions. Moreover, it is not possible to provide a blanket, empiric recommendation
for CP discontinuation without testing.
Our study found that exposure to carbapenems was associated with prolonged
CPE carriage; this highlights the importance of antimicrobial stewardship interventions to
prevent unnecessary exposures to carbapenems that might select resistant strains that
facilitate prolonged CPE carriage and increase the risk of infections by these organisms.
We recently reported the development of algorithms for testing of carbapenem resistant
Gram-negative rods; before implementation of these algorithms, the identification of CPE
took a median time of 5 days, delaying timely treatment and implementation of proper
isolation precautions 27. Further research should aim to evaluate the effect of such
interventions to shorten time to appropriate therapy and the effect in the time to CPEcarriage clearance.
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Furthermore, previous studies suggested differences in the duration of CPE
carriage based on the type of carbapenemase produced with KPC-producing isolates
showing a longer duration of colonization compared to NDM-producing isolates24. In this
study, we were unable to find similar results since most of the CPE tested were KPCproducing with limited representation of other carbapenemases; further studies are
needed to assess possible differences in duration of CPE carriage based on the type of
carbapenemase produced.
Our study had several limitations. First, we had a small sample size that might
limit the power to detect the effect that certain predictors might have over the time for
clearance of CPE carrier status. Second, in our institution, only patients admitted into an
adult ICU had surveillance cultures collected routinely; this introduced selection bias to
the study limiting the generalizability of our findings by excluding the patient population
that has never been admitted to an ICU. Future studies should assess factors associated
with prolonged CPE carriage among non-ICU patients and those in the community
without hospital exposure. Furthermore, 50% of eligible patients were excluded due to
limited follow up surveillance cultures which could have biased our results. Additionally,
at the time of the study, the laboratory procedure test used for the surveillance cultures
was not very sensitive, introducing potential measurement bias. Using more than one
surveillance culture and requiring agreement with the initial anatomical source of CPE
isolation likely compensated for the lower sensitivity of the procedure.
Conclusion
In conclusion, infection prevention and antimicrobial stewardship practices
should consider risk factors for prolonged CPE carriage to limit transmission and select
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suitable treatment options to optimize success at eradication, limit transmission, and
safely discontinue isolation precautions. Further studies are needed to identify risk factors
for long-term CPE carriage in different populations and to clarify possible differences for
duration of CPE carriage related to microorganism specific species and type of
carbapenemase.
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Table 1. Characteristics of CPE carriers at a large health care system 2012–2016
CPE Carrier
Cleared
N= 25 (%)

Chi
square
p-value

Sex, Female

CPE
Carrier
Not
Cleared
N= 50 (%)
24 (48)

17 (68)

0.101

Age, mean (± SD)

64 (14.3)

54.1 (18.8)

0.014*

Home

23 (46)

9 (36)

0.845

Other hospital

12 (24)

8 (32)

LTCF

11 (22)

6 (24)

4 (8)

2 (8)

Solid organ transplant

11 (22)

8 (32)

0.348

Immunocompromised

19 (38)

14 (56)

0.139

Steroids >2 weeks

9 (18)

7 (28)

0.319

Surgery

30 (60)

17 (68)

0.500

Endoscopy

14 (29)

10 (40)

0.350

ICU admission

40 (80)

22 (88)

0.388

5.34 (2.8)

Admission source

Overseas

Charlson score , mean (± SD)

5.12 (2.6)

0.745*

Diabetes mellitus with end organ
damage
Congestive heart failure

4 (8)

2 (8)

0.352

7 (14)

1 (4)

0.186

Myocardial infarction

6 (12)

2 (8)

0.597

Peripheral vascular disease

5 (10)

1 (4)

0.367

Chronic kidney disease

15 (30)

7 (28)

0.858

Cardiovascular disease

8 (16)

2 (8)

0.337

Chronic obstructive pulmonary
disease
Connective tissue disease

7 (14)

1 (4)

0.186

2 (4)

0(0)

0.311

Moderate to severe liver disease

2 (4)

7 (28)

0.005

Localized solid tumor

3 (6)

2 (8)

0.423

Metastatic solid tumor

1 (2)

2 (8)

Human immunodeficiency virus

3 (6)

2 (8)

0.743

Central venous catheter exposure

30 (60)

18 (72)

0.307

Indwelling urinary catheter exposure

32 (64)

14 (56)

0.502

Ventilator exposure

22 (44)

14 (56)

0.327

Klebsiella spp.

27 (54)

19 (76)

0.179

Enterobacter spp.

10 (20)

1 (4)

Escherichia coli

4 (8)

2 (8)

Serratia marcescens

4 (8)

0(0)

Citrobacter spp.

5 (10)

3 (12)

blaKPC

34 (68)

18 (72)

Comorbidities

Organism

Carbapenemase

66

0.792

gene

blaNDM

2 (4)

1 (4)

blaSME

2 (4)

0(0)

Unknown/not tested

12 (24)

6 (24)

Rectal

5 (10)

7 (28)

Blood

0 (0)

1 (4)

Urine

23 (46)

6 (24)

Respiratory

18 (36)

8 (32)

Wound/drainage

3 (6)

2 (8)

Other

1 (2)

1 (4)

CPE isolated from >1 body site

36 (72)

14 (56)

0.166

Antibiotic exposure

48 (96)

25 (100)

0.311

< 4 days

3 (6)

1 (4)

0.280

4-7 days

5 (10)

0(0)

8-18 days

7 (14)

2 (8)

> 18 days

35 (70)

22 (88)

None

2 (4)

0(0)

1

3 (6)

0(0)

2

2 (4)

1 (4)

3-4

9 (18)

4 (16)

>4

34 (68)

20 (80)

Aminoglycosides

17 (34)

13 (52)

0.134

1st -2nd gen cephalosporins

2 (4)

3 (12)

0.190

3rd- 4th gen cephalosporins

34 (68)

19 (76)

0.473

Carbapenems

32 (64)

23 (92)

**0.010

Daptomycin

7 (14)

3 (12)

0.810

Vancomycin

41 (82)

23 (92)

0.249

Macrolides

5 (10)

4 (16)

0.451

Quinolones

25 (50)

16 (64)

0.251

Metronidazole

21 (42)

11 (44)

0.869

Sulfas

17 (34)

13 (52)

0.134

Colistin

21 (42)

12 (48)

0.622

Penicillins

24 (48)

14 (56)

0.514

3 (6)

1 (4)

0.716

28 (56)

13 (52)

0.743

Initial carriage
source

Antibiotic days

Number of
antibiotics

Antibiotic class

Ceftazidime/avibactam
Other

0.163

0.580

Mortality at 30 days

8 (16)

1(4)

0.132

Overall mortality

19 (38)

10 (40)

0.867

CPE= carbapenemase-producing Enterobacteriaceae; SD = standard deviation; LTCF= long-term-care
facility; ICU =intensive care unit; COPD= Chronic obstructive pulmonary disease; AIDS = Acquired
immunodeficiency syndrome.
*t-test P-value
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Table 2. Predictors for clearance of CPE carriage at a large health care system in South Florida, 2012–2016
Univariable
95% CI
p-value Multivariable
Hazard
Hazard ratio
ratio
Gender
Female
0.70
0.46-1.06 *0.093
0.71
Age, mean
Admission source

0.99

0.96-1.01

p-value

0.281.70

0.416

0.150.93

**0.034

0.258

Home

Ref

Other hospital

0.67

0.35-1.31

0.244

LTCF

0.86

0.43-1.70

0.670

Overseas

1.11

0.53-2.33

0.776

Solid organ transplant

1.49

0.64-3.48

0.354

Immunocompromised

0.65

0.43-0.97

**0.036

Steroids >2 weeks

0.79

0.51-1.23

0.298

Surgery

0.96

0.63-1.46

0.836

Endoscopy

1.19

0.53-2.67

0.667

ICU admission

0.65

0.35-1.18

0.158

Charlson score

1.15

0.95-1.39

0.145

Diabetes mellitus with end organ
damage
Congestive heart failure

0.641

0.29-1.39

0.258

1.373

0.50-3.76

0.538

Myocardial infarction

1.43

0.69-2.96

0.329

Peripheral vascular disease

1.64

0.60-4.48

0.330

Chronic kidney disease

0.93

0.59-1.48

0.759

Cardiovascular disease

1.44

0.70-2.97

0.322

Comorbidities

95% CI

0.668
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0.38

Devices

Organism

Carbapenemase
gene

COPD

1.49

0.55-4.01

0.438

Chronic lung disease

1.30

0.48-3.53

0.611

Connective tissue disease

0.04

0.440

Liver disease

0.72

0.00115.7
0.46-1.11

HIV

1.10

0.26-4.69

0.895

Central Venous catheter

0.73

0.47-1.13

0.16

Indwelling urinary catheter

1.11

0.75-1.65

0.611

Ventilator

0.70

0.47-1.04

*0.075

Klebsiella spp.

0.38

0.160.92

**0.031

5.01

2.0312.36

**<0.001

0.14

0.030.63

**0.011

0.520

Enterobacter spp.

0.21

0.03-1.56

0.127

Escherichia coli

0.59

0.14-2.54

0.476

Citrobacter spp.

0.56

0.17-1.93

0.362

Serratia marcescens

0.00

0.00

0.980

blaKPC

ref

blaNDM

1.26

0.50-3.19

0.624

blaSME

0.89

0.11-7.46

0.914

Unknown/not tested

0.00

0.00

0.982

2.05

0.93-4.52

*0.075

Aminoglycosides

0.84

0.57-1.25

0.393

1st -2nd gen cephalosporins

0.93

0.50-1.70

0.802

3rd- 4th gen cephalosporins

1.06

0.67-1.68

0.810

Carbapenem

0.50

0.24-1.03

*0.062

Daptomycin

1.03

0.56-1.88

0.928

CPE isolated from >1 body site
Antibiotic
exposure

ref

0.137

0.956
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Vancomycin

0.77

0.37-1.59

0.480

Macrolides

1.14

0.67-1.96

0.626

Quinolones

0.96

0.63-1.44

0.826

Metronidazole

1.15

0.76-1.72

0.509

Sulfas

0.87

0.54-1.28

0.477

Colistin

0.98

0.66-1.46

0.930

Penicillins

1.07

0.72-1.59

0.736

Other

1.11

0.75-1.64

0.612

Ceftazidime/avibactam (CZA)

1.34

0.49-3.64

0.570

* p-value <0.1
** p-value <0.05
CPE = Carbapenemase-producing Enterobacteriaceae; CI = confidence interval; SD= standard deviation; LTCF = long-term-care
facility; ICU= Intensive care unit.
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Table 3. Predictors for Clearance of CPE Carrier status at a Healthcare System in
Miami, FL 2012–2016—Reduced Model.
aHR

95%CI

P-value

Ventilator

0.34

0.14-0.82

*0.016

Immunocompromised

0.34

0.14-0.80

*0.014

Carbapenems exposure

0.14

0.03-0.62

*0.010

CPE isolated from >1 body site

5.27

2.12-13.07

*<0.001

* P-value ≤0.05
CPE= carbapenemase-producing Enterobacteriaceae; aHR = Adjusted Hazard
ratio; CI = confidence interval

Figure 1.
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CONCLUSIONS
The epidemiology of carbapenem-resistant Enterobacteriaceae (CRE) among a
cohort of patients admitted to an acute-care setting in Miami, FL is similar to that
described in other highly populated areas in the US. Klebsiella pneumoniae was the most
frequent species of CRE identified. Similarly, KPC was the most frequent carbapenemase
detected. CRE accounted for 2% of all the Enterobactericeae tested during the study
period; this percentage is similar to the current estimate for Florida (2.1%) and lower than
the one for the US (2.7%).
The use of an internal CRE registry integrated with the EMR contributed to the control of
increasing CRE rates by rapidly identifying readmissions and allowing immediate
initiation of proper isolation, infection prevention interventions, and appropriate
antimicrobial stewardship management. Similar registries implemented at a regional or
state level would have a greater impact on controlling the spread of CRE across the US
by allowing automatic electronic identification of known CRE carriers transferred or
admitted to different healthcare system networks. This would also allow public health
authorities to allocate adequate resources for their HAI prevention programs and target
regions with higher numbers of CRE reported to the registry.
In the same way, active surveillance testing is a key component in controlling the spread
of CRE/CPE by increasing the early detection of carriers and facilitating the timely
implementation of infection prevention strategies. Active surveillance testing should
include populations at risk for CRE carriage. The ICU population has been widely
recognized as being at higher risk for the acquisition of these organisms. Moreover, the
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surveillance-testing program should incorporate populations at risk admitted to acute care
units but not necessarily to the ICU such as patients transferred from overseas or longterm-care facilities. Additionally, the program should involve screening in more than one
anatomical site to increase the sensitivity of the program particularly for those on a
mechanical ventilator. It is also important that the surveillance testing program include
differentiation of the type of carbapenemases facilitating proper patient/staff cohorting
and targeted treatment selection.
Not all CPE-colonized patients develop infections by these organisms; this study found
that 30% of the CPE-colonized patients developed an infection within 7 months of
colonization detection. A site of colonization that is frequently forgotten by CPE
colonization-related studies is the respiratory tract; most studies rely on rectal
colonization. This study found that a higher percentage of patients colonized in the
respiratory tract developed infection compared to those colonized rectally or in the
urinary tract; once again this highlights the importance of considering screening patients
in more than one anatomical site for CRE/CPE. Similarly, the use of indwelling urinary
catheters has been linked to a higher risk for infection; in this study, it was associated
with a higher risk for the development of CPE infection among colonized patients. We
strongly suggest implementing alternatives to the use of these devices such as condom
catheters or external female catheters; daily assessment of the necessity of indwelling
urinary catheters should be a regular practice at the bedside aiming to reduce not only
CAUTI, but also CPE infections.
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In addition, this study evaluated the duration of CPE-carriage finding a median time for
clearance of 80 days; moreover, long-term carriage was detected for up to 42 months.
The findings of this study indicate that discontinuation of contact precautions for CPE
should be evaluated on a case-by-case basis as suggested by European guidelines. This
evaluation should at least 80 days after carriage detection and should include more than
one negative surveillance culture as well as agreement with the original site of carriage; it
should also take into account the presence of risk factors such as exposure to
carbapenems, or mechanical ventilators.
This study also found a higher risk for the development of CPE infection among
colonized patients that were exposed to intravenous colistin. Similarly, the study found
long-term CPE carriage associated with exposure to carbapenem. Increasing early
detection of CRE/CPE has effects in rapid antimicrobial stewardship interventions that
promote the appropriate selection of antibiotics preventing unnecessary exposures to
carbapenems and preserving the limited available options for treatment of these
organisms. Interdisciplinary approaches that incorporate infection prevention,
antimicrobial stewardship, and microbiology teams are pivotal in controlling the spread
of CRE/CPE globally.
Treatment and management of CRE/CPE continue to be challenging for healthcare
facilities in the US. This dissertation project unveils several opportunities for future
research. During the study period, new antibiotic combinations such as ceftolozanetazobactam or ceftazidime-avibactam were not widely available; future studies should
look at the effect of exposures to these antibiotics in the development of CPE infections
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among colonized patients as well as in long-term CPE carriage. New studies should also
evaluate the effect of interventions aimed to reduce the time to appropriate therapy in the
duration of carriage and in controlling the spread of CRE/CPE.
In this study we did not include interventions such as selective decolonization or fecal
transplantation for CPE colonization management; more studies are necessary that
include such interventions and investigate its role in duration of CPE carriage.
Prospective studies can also evaluate the effect of disrupting the gut microbiome in the
development of CPE infections among colonized patients as well as in duration of CPE
carriage.
Most of the carbapenemases identified in this project were KPC, with little or no
representation of other ones such as NDM, VIM, or OXA; these results did not allow for
comparisons of duration of CPE carriage among different carbapenemases. Larger studies
are necessary that allow for such comparisons. Some carbapenemases might be more
common among other Gram-negative bacilli such as Pseudomonas; studying other
carbapenemase-producing organisms might bring a different insight to the management
of extensively drug-resistant organisms in the healthcare setting.
Lastly, similar studies can evaluate epidemiological trends, risks for development
of infections among colonized patients, and duration of carriage related to other emergent
multidrug resistant organism such as Candida auris, carbapenem-resistant Acinetobacter,
or Clostridioides difficile. These multidrug resistant organisms are also considered urgent
threats by the CDC and are of increasing concern because of their rapid spread around the
world.
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